FTC Wants More Info On $4.8B Roche Buy Of Swiss Gene Co.

Law360 (June 11, 2019, 1:15 PM EDT) -- The Federal Trade Commission wants more information before it decides whether to sign off on Swiss pharmaceutical company Roche’s $4.8 billion plan to buy gene therapy company Spark Therapeutics.

F. Hoffmann-La Roche AG broke the news Monday that the FTC had sent out the so-called second request for information, which the agency makes if its initial review of a proposed deal raises any competition concerns.

“The parties remain committed to the transaction and are working cooperatively and expeditiously with the FTC in connection with its review,” Roche said in a statement.

The request from the agency has forced Roche to push...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS